12. Huang, L.; Huang, Z.; Bai, Z.; Xie, R.; Sun, L.; Lin, K. Development and strategies of VEGFR-2/KDR inhibitors.
Future. Med. Chem. 2012; 4:1839-1852.
13. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004;
25:581-611.
14. Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-Ward, R. G.; Epperly, A. H.; Hinkle, K.
W.; Hunter, R. N., III; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.;
Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. Discovery of
5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide
(pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 2008;
51:4632-4640.
15. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S.
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006;
5:835-844.
16. Strumberg, D.; Scheulen, M. E.; Schultheis, B.; Richly, H.; Frost, A.; Buechert, M.; Christensen, O.; Jeffers, M.;
Heinig, R.; Boix, O.; Mross, K. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Brit.
J. Cancer 2012; 106:1722-1727.
17. Ratain, M. J.; Eisen, T.; Stadler, W. M.; Flaherty, K. T.; Kaye, S. B.; Rosner, G. L.; Gore, M.; Desai, A. A.;
Patnaik, A.; Xiong, H. Q.; Rowinsky, L.; Abbruzzese, J. L.; Xia, C. H.; Simantov, R.; Schwartz, B.; O'Dwyer, P. J.
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell
carcinoma. J. Clin. Oncol. 2006; 24:2505-2512.
18. Shang, X.-F.; Morris-Natschke, S. L.; Yang, G.-Z.; Liu, Y.-Q.; Guo, X.; Xu, X.-S.; Goto, M.; Li, J.-C.; Zhang,
J.-Y.; Lee, K.-H. Biologically active quinoline and quinazoline alkaloids part II. Med. Res. Rev. 2018;
38:1614-1660.
19. Resende, D. I. S. P.; Boonpothong, P.; Sousa, E.; Kijjoa, A.; Pinto, M. M. M. Chemistry of the fumiquinazolines
and structurally related alkaloids. Nat. Prod. Rep. 2018; 36:7-34
20. Murugesan, D.; Ray, P. C.; Bayliss, T.; Prosser, G. A.; Harrison, J. R.; Green, K.; Soares de Melo, C.; Feng, T. S.;
Street, L. J.; Chibale, K.; Warner, D. F.; Mizrahi, V.; Epemolu, O.; Scullion, P.; Ellis, L.; Riley, J.; Shishikura, Y.;
Ferguson, L.; Osuna-Cabello, M.; Read, K. D.; Green, S. R.; Lamprecht, D. A.; Finin, P. M.; Steyn, A. J. C.;
Ioerger, T. R.; Sacchettini, J.; Rhee, K. Y.; Arora, K.; Barry, C. E., 3rd; Wyatt, P. G.; Boshoff, H. I. M.
2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis:
Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion
Characterization. ACS Infect. Dis. 2018; 4:954-969.
21. Hudson, L.; Mui, J.; Vazquez, S.; Carvalho, D. M.; Williams, E.; Jones, C.; Bullock, A. N.; Hoelder, S. Novel
Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship,
Structural Characterization, Kinase Profiling, and Cellular Proof of Concept. J. Med. Chem. 2018; 61:7261-7272.
22. Ferreira de Freitas, R.; Harding, R. J.; Franzoni, I.; Ravichandran, M.; Mann, M. K.; Ouyang, H.; Lautens, M.;
Santhakumar, V.; Arrowsmith, C. H.; Schapira, M. Identification and Structure-Activity Relationship of HDAC6
Zinc-Finger Ubiquitin Binding Domain Inhibitors. J. Med. Chem. 2018; 61:4517-4527.
23. Alagarsamy, V.; Chitra, K.; Saravanan, G.; Solomon, V. R.; Sulthana, M. T.; Narendhar, B. An overview of
quinazolines: Pharmacological significance and recent developments. Eur. J. Med. Chem. 2018; 151:628-685.
24. Nathubhai, A.; Haikarainen, T.; Koivunen, J.; Murthy, S.; Koumanov, F.; Lloyd, M. D.; Holman, G. D.;
Pihlajaniemi, T.; Tosh, D.; Lehtio, L.; Threadgill, M. D. Highly Potent and Isoform Selective Dual Site Binding
Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity. J.
Med. Chem. 2017; 60:814-820.
25. Li, S.; Ma, J.-A. Core-structure-inspired asymmetric addition reactions: enantioselective synthesis of
13